Edgewood Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2023-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Edgewood Oncology Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT04872166
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸The Linder Research Center at The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Edgewood Oncology Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04243785
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States